Subscribe to
this category


A total of 9 posts are filed under Pricing
Measuring the Value of Therapies for Ultra-Rare Diseases
  The pricing of drugs is characterized by a tension between providing incentives to drug companies to invest in the development of… Continue Reading
Duchenne UK Collaborates with Industry to Speed Payer Value Assessments
Rare Daily Staff Duchenne UK has launched a collaboration with five pharmaceutical companies developing treatments for Duchenne muscular… Continue Reading
ICER Issues Modified Framework for Assessing Value of Treatments for Ultra-Rare Diseases
Rare Daily Staff The Institute for Clinical and Economic Review, an independent non-profit research institute that analyzes the evidence on… Continue Reading
Paying for Value
The drug industry long justified the pricing of its products on the basis of the high cost of R&D and the need for successes to offset the… Continue Reading
Canadian Drug Watchdog Orders Alexion to Lower Price of Soliris, Refund Overcharges
Rare Daily Staff A Patented Medicine Prices Review Board Hearing Panel found Alexion Pharmaceuticals’ rare disease drug Soliris pricing… Continue Reading
New Therapies Pushing Orphan Drug Prices into Payers’ Crosshairs
Daniel S. Levine Rare disease therapies have been largely immune to the pricing battles over drugs, but controversy over the costs of new… Continue Reading